Ukadike Kennedy C, Mustelin Tomas
Division of Rheumatology, Department of Medicine, University of Washington School of Medicine, 750 Republican Street, Seattle, WA 98109, USA.
J Clin Med. 2021 Feb 19;10(4):856. doi: 10.3390/jcm10040856.
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease. While its etiology remains elusive, current understanding suggests a multifactorial process with contributions by genetic, immunologic, hormonal, and environmental factors. A hypothesis that combines several of these factors proposes that genomic elements, the L1 retrotransposons, are instrumental in SLE pathogenesis. L1 retroelements are transcriptionally activated in SLE and produce two proteins, ORF1p and ORF2p, which are immunogenic and can drive type I interferon (IFN) production by producing DNA species that activate cytosolic DNA sensors. In addition, these two proteins reside in RNA-rich macromolecular assemblies that also contain well-known SLE autoantigens like Ro60. We surmise that cells expressing L1 will exhibit all the hallmarks of cells infected by a virus, resulting in a cellular and humoral immune response similar to those in chronic viral infections. However, unlike exogenous viruses, L1 retroelements cannot be eliminated from the host genome. Hence, dysregulated L1 will cause a chronic, but perhaps episodic, challenge for the immune system. The clinical and immunological features of SLE can be at least partly explained by this model. Here we review the support for, and the gaps in, this hypothesis of SLE and its potential for new diagnostic, prognostic, and therapeutic options in SLE.
系统性红斑狼疮(SLE)是一种异质性自身免疫性疾病。尽管其病因仍不明确,但目前的认识表明这是一个多因素过程,涉及遗传、免疫、激素和环境因素。一种综合了其中几个因素的假说提出,基因组元件L1逆转录转座子在SLE发病机制中起作用。L1逆转录元件在SLE中被转录激活,并产生两种蛋白质,即开放阅读框1蛋白(ORF1p)和开放阅读框2蛋白(ORF2p),它们具有免疫原性,可通过产生激活胞质DNA传感器的DNA种类来驱动I型干扰素(IFN)的产生。此外,这两种蛋白质存在于富含RNA的大分子聚集体中,这些聚集体还包含Ro60等著名的SLE自身抗原。我们推测,表达L1的细胞将表现出被病毒感染的细胞的所有特征,从而引发类似于慢性病毒感染中的细胞和体液免疫反应。然而,与外源病毒不同,L1逆转录元件无法从宿主基因组中消除。因此,L1失调将给免疫系统带来慢性但可能是间歇性的挑战。SLE的临床和免疫学特征至少可以部分地用这个模型来解释。在此,我们综述了对这一SLE假说的支持证据、存在的差距及其在SLE新诊断、预后和治疗选择方面的潜力。